CN107099491A - Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared - Google Patents
Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared Download PDFInfo
- Publication number
- CN107099491A CN107099491A CN201710542452.6A CN201710542452A CN107099491A CN 107099491 A CN107099491 A CN 107099491A CN 201710542452 A CN201710542452 A CN 201710542452A CN 107099491 A CN107099491 A CN 107099491A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- constipation
- mouse
- lactobacillus
- activated carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 79
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 79
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 79
- 206010010774 Constipation Diseases 0.000 title claims abstract description 63
- 235000013305 food Nutrition 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 108020004999 messenger RNA Proteins 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 28
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 22
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 20
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 20
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 238000003757 reverse transcription PCR Methods 0.000 description 16
- 210000000813 small intestine Anatomy 0.000 description 16
- 230000003321 amplification Effects 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 102000003566 TRPV1 Human genes 0.000 description 13
- 101150016206 Trpv1 gene Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 12
- 241000193830 Bacillus <bacterium> Species 0.000 description 11
- 210000001809 melena Anatomy 0.000 description 11
- 102000012440 Acetylcholinesterase Human genes 0.000 description 10
- 108010022752 Acetylcholinesterase Proteins 0.000 description 10
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 10
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 10
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 10
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 10
- 229940022698 acetylcholinesterase Drugs 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229940099352 cholate Drugs 0.000 description 8
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 210000004495 interstitial cells of cajal Anatomy 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 235000013618 yogurt Nutrition 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000005176 gastrointestinal motility Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical class C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- -1 GelRed nucleic acid Chemical class 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009654 indole test Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
It is CCTCC NO the invention discloses deposit number：M2016749 Lactobacillus plantarum YS3 (Lactobacillus plantarum YS3) and its application in the food of Constipation is prepared, not only expand Lactobacillus plantarum YS3 application, its application value is improved, and new hope is brought to the prevention of constipation.
Description
Technical field
The invention belongs to microbial technology field, it is related to a kind of Lactobacillus plantarum and its application in food is prepared.
Background technology
Yak yogurt is a kind of spontaneous fermentation dairy products in Qinghai-Tibet Tibetan area, contains abundant nutritional ingredient, tool
There are anti-oxidant, reduction cholesterol, regulation immunity.Due to special spontaneous fermentation condition, including fermentation raw material breast, hair
Ferment temperature, fermentation time, fermentation vessel, particularly special fermentative microorganism composition, cause yak yogurt to have flavour
And quality.
Constipation state can be considered at when defecation frequency is less than 3 times weekly, when number of times is considered as seriously less than 1 time
Constipation state, be it is a kind of threaten health, particularly there is the complicated symptom of considerable influence to colon health.Constipation is usual
Disease is not considered as, majority of case can pass through diet and the regulation Constipation of custom.
The content of the invention
Carried out it is an object of the invention to carry out separation identification to the microorganism in yak yogurt, and to its activity and application
Research.
Through research, the present invention provides following technical scheme：
1. Lactobacillus plantarum YS3 (Lactobacillus plantarum YS3), deposit number is CCTCC NO：
M2016749。
2. applications of the Lactobacillus plantarum YS3 in the food of Constipation is prepared.
The present invention has carried out separation identification to the microorganism in the yak yogurt of Yushu district, Qinghai Tibetan autonomous prefecture, will wherein one
Lactobacillus plantarum (Lactobacillus plantarum) is named as YS3, and Chinese Typical Representative is preserved on December 14th, 2016
Culture collection (abbreviation CCTCC, address：No. 299 Wuhan Universitys of Wuhan City, Hubei Province Wuchang District Bayi Road), deposit number
For CCTCC NO：M2016749.
Activated carbon inducing constipation model mice result of study shows that Lactobacillus plantarum YS3 anti-hydrochloric acid in gastric juice and cholate ability is strong
In lactobacillus bulgaricus, the mouse weight decline that constipation is caused can be suppressed, stool weight, granule number and water content decline,
Propulsion rate of the activated carbon in small intestine can be improved simultaneously, reduce the time of the first grain melena of discharge, moreover it is possible to make the blood of mice with constipation
Clearing stomach therbligs (MTL), gastrin (Gas), Endothelin (ET), acetylcholinesterase (AChE), Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (SP) and vasoactive
Peptide (VIP) serum levels are improved, and growth hormone release inhibiting hormone (SS) level declines.RT-PCR experimental results further show, Lactobacillus plantarum
YS3 can raise c-Kit, SCF, GDNF mRNA in mice with constipation small intestine and express, and lower TRPV1, NOS mRNA expression.
The Lactobacillus plantarum YS3 of high concentration shows more preferable effect, and is significantly better than the lactobacillus bulgaricus of same concentration.These realities
Testing result proves, Lactobacillus plantarum YS3 can effectively suppress constipation, can be used in preparing the food of Constipation.
The beneficial effects of the present invention are：The invention provides a kind of Lactobacillus plantarum YS3, it can effectively suppress just
It is secret, and effect is significantly better than conventional lactobacillus bulgaricus, can be used in preparing the food of Constipation, not only expands plant
Thing lactobacillus YS3 application, improves its application value, and bring new hope to the prevention of constipation.
Brief description of the drawings
Fig. 1 is the agarose gel electrophoresis figure of Lactobacillus plantarum YS3 genomic DNA, and wherein M is λ DNA/Hind III
Marker, 1 is Lactobacillus plantarum YS3 genomic DNA.
Fig. 2 is the PCR amplifications of Lactobacillus plantarum YS3 16S rDNA genetic fragments, and wherein M is DNA Marker, C
It is the pcr amplification product of Lactobacillus plantarum YS3 16S rDNA genetic fragments for negative control, 1.
Fig. 3 is influences of the Lactobacillus plantarum YS3 to activated carbon inducing constipation mouse weight.
Fig. 4 is influences of the Lactobacillus plantarum YS3 to activated carbon inducing constipation small mouse's head grain melena efflux time.
Fig. 5 is that Lactobacillus plantarum YS3 is expressed c-Kit and SCF mRNA in activated carbon inducing constipation mouse small intestine tissue
Influence.
Fig. 6 is Lactobacillus plantarum YS3 to TRPV1, GDNF and NOS mRNA in activated carbon inducing constipation mouse small intestine tissue
The influence of expression.
Fig. 3 is into Fig. 6, and LB represents lactobacillus bulgaricus, and LP-YS3 represents Lactobacillus plantarum YS3.
Embodiment
In order that the object, technical solutions and advantages of the present invention are clearer, below in conjunction with accompanying drawing to the excellent of the present invention
Embodiment is selected to be described in detail.
The separation and identification of embodiment 1, Lactobacillus plantarum YS3
First, lactic acid bacteria isolates and purifies
Gather 10 parts of the spontaneous fermentation yak yogurt sample of Yushu district, Qinghai Tibetan autonomous prefecture herdsman family, every part of sample nothing
After bacterium glass rod is fully stirred evenly, draw 50mL and be put into sterile centrifugation tube, be placed in food sampling box and take back laboratory, 4 DEG C of refrigerators
Preserve.
Every part of yak yogurt sample takes 1mL, and 10 times of gradient dilutions are made to 10 with sterile saline-7.Take 10-5、10-6、
10-7Each 1mL dilutions of three dilution factors respectively at equipped with 15mL MRS culture mediums (containing mass ratio be 5% CaCO3) plate
In, mix, put 30 DEG C of 72 ± 3h of insulating box culture.Each three, dilution factor work is parallel.After bacterium colony is formed, its form is observed special
Levy, the different bacterium colonies that picking has molten calcium circle are inoculated in degreasing milk medium respectively, put 30 DEG C of 24~48h of culture, treat that bacterial strain is given birth to
After length is good, streak inoculation puts 30 DEG C of culture 48h in MRS agar mediums；Above step is repeated at least three times, until obtaining
Pure bacterium colony.
Pure bacterial strain is rule on MRS solid mediums, 30 DEG C of culture 48h are put, with 10 times of amplification sem observation bacterium colony sizes,
The appearance features such as shape, carry out Gram's staining, and the typical bacterial strain of picking form carries out catalase test.Gram is contaminated
Color is positive, catalase test is negative meningitidis strains and bacillus strain, are fixed tentatively as lactic acid bacteria.
2nd, the identification of Bacillus acidi lactici
By the lactic acid bacillus mycopremna that preliminary screening goes out carry out respectively growth temperature experiment (10 DEG C, 15 DEG C, 45 DEG C, 60 DEG C,
30min), pH value gradient test, mobility test, catalase test, oxidase test, hydrogen sulfide production test, gelatin liquefaction experiment,
Nitrate reduction test, indole test, the experiment of glucose aerogenesis, benzidine test, litmus milk tests, arginine production ammonia examination
Test, casein decomposition run and various sugar alcohol fermentation tests.
As a result isolated from 10 parts of yak yogurt samples and be purified into 20 plants of Bacillus acidi lacticis, be Gram-positive,
Catalase test is negative.By morphological observation and physiological and biochemical test, this 20 plants of bacterial strains are initially identified as 7 kinds of lactic acid
Bacillus, number consecutively is Lb1~Lb7, wherein, numbering is Lb6 Bacillus acidi lactici is initially identified as Lactobacillus plantarum
(Lactobacillus plantarum) (table 1).
The numbering of table 1 is LbThe morphological feature and physiological and biochemical test result of 6 Bacillus acidi lactici
Note：+, it is positive；-, it is negative；+ w, weakly positive.
3rd, the identification of Lactobacillus plantarum
It is L to take numberingbSupernatant is abandoned in the bacteria suspension of 6 Bacillus acidi lactici Liquid Culture, centrifugation, thalline is collected, according to bacterium base
Because a group DNA extraction kit (Beijing Suo Laibao scientific ＆ technical corporation) methods described extracts genomic DNA, enter row agarose gel electrophoresis
(gel mass concentration ratio 0.8%, voltage 80V, electrophoresis 80min), after GelRed nucleic acid staining dyes, in gel imaging system
Middle observation (Fig. 1).The genomic DNA of extraction is diluted 200 times, concentration purity testing is carried out with ultraviolet specrophotometer.Using
Primer 2 7F：5 '-AGAGTTTGATCCTGGCTCAG-3 ' (SEQ ID No.1) and 1492R：5’-
GGCTACCTTGTTACGACTT-3 ' (SEQ ID No.2) enters performing PCR amplification (Fig. 2) to 16S rDNA genetic fragments.Amplification production
Thing is sequenced by Sangon Biotech (Shanghai) Co., Ltd. and Beijing Liuhe Huada Genomics Technology Co., Ltd, and will
Sequencing result (SEQ ID No.3) is compared with correlated series in Genbank.As a result show, numbering is Lb6 Bacillus acidi lactici
The similitude of 16S rDNA gene fragment orders and Lactobacillus plantarum strain CIP 103151 reach
99%.
Therefore, numbering is Lb6 Bacillus acidi lactici is accredited as Lactobacillus plantarum (Lactobacillus plantarum), will
It is named as YS3, and is preserved in China typical culture collection center (abbreviation CCTCC, address on December 14th, 2016：Lake
No. 299 Wuhan Universitys of Bayi Road of Bei Sheng wuchang, wuhan area), deposit number is CCTCC NO：M2016749.
The prevention effect of embodiment 2, Lactobacillus plantarum YS3 to activated carbon inducing mouse constipation
By making gastrointestinal tract mucous surface be adhered to by activated carbon to mouse stomach activated carbon, cause in alimentary canal under water content
Drop, digestive juice is reduced, and triggers gastrointestinal motility to slow down to form constipation.In the early-stage Study to lactic acid bacteria constipation preventive effect, hair
A person of good sense confirms that first grain melena defecation time, MTL, Gas, ET, SS, AChE, SP, VIP level etc. all can be as evaluation lactic acid bacterias
The index of constipation prevention effect；Detect that correlation mRNA expression can be more true in colon by further molecular biology experiment
The physiological function of the confirmation lactic acid bacteria cut.
Main material, instrument and the experimental animal that the present embodiment is used are as follows：Lactobacillus plantarum YS3 (preserving numbers：CCTCC
NO：M2016749), lactobacillus bulgaricus (Chinese industrial Microbiological Culture Collection administrative center)；MTL、Gas、ET、SS、
AChE, SP and VIP (Beijing pul great achievement bio tech ltd)；Trizol reagents, OligodT18、RNase、dNTP、MLV
Reverse transcriptase (Invitrogen companies of the U.S.)；ROX reference Dye and SYBR Premix Ex Taq II (Japan
TAKARA companies)；RT-PCR primer (Beijing Tiangeng biochemical technology Co., Ltd).D550 digital cameras (Japan Canon)；
SevenEasy pH meters (Mettler Toledo Inc. of Switzerland)；(U.S. Bole is public for iMark ELIASAs, T100 grads PCRs instrument
Department).Seven week old female KM mouse are purchased from Medical University Of Chongqing's Experimental Animal Center (credit number：SYXK (Chongqing) 2012-
0001), raise in temperature and humidity control environment (25 ± 2 DEG C of temperature, relative humidity 50 ± 5%), light dark cycles are adjusted per 12h, are carried
For mouse standard feed and drinking-water.
First, the anti-hydrochloric acid in gastric juice abilities of Lactobacillus plantarum YS3 and the detection of cholate tolerance
Lactic acid bacteria will play probiotic action, it is necessary under the strong acidic condition of stomach and enteron aisle, arrive at (typically
Large intestine) it is colonized and plays its physiological function.Therefore, in order to study the potential probiotic action of lactic acid bacteria, external virtual mould is set up
Type, the anti-hydrochloric acid in gastric juice ability and cholate tolerance for detecting lactic acid bacteria are important detection means.
It is 3.0 to be dissolved in distilled water and adjust pH with 1mol/L HCl NaCl and pepsin, reaches NaCl quality
It is 0.35% than the mass ratio for 0.2%, pepsin, vacuum filter removes bacterium, standby as simulated gastric fluid.By plant breast
Cultivated after bacillus YS3 activation, take nutrient solution 5mL, 3000r/min centrifugation 10min, thalline is collected, with 5mL physiological saline weights
After outstanding, mixed at 1: 9 by volume with simulated gastric fluid, 37 DEG C of culture 3h determine Lactobacillus plantarum YS3 viable counts during 0h and 3h,
Survival rate (%)=3h viable count (CFU/mL)/0hs of the Lactobacillus plantarum YS3 in the simulated gastric fluids of pH 3.0 is calculated by formula to live
Bacterium number (CFU/mL) × 100.
It is 0.0,0.3%, 0.5%, 1.0% that Lactobacillus plantarum YS3 is inoculated in containing mass ratio by 2% inoculum concentration
The MRS-THIO culture mediums of bovine bile, 37 DEG C of culture 24h, using non-inoculated plant lactobacillus YS3 blank cultures as control,
Absorbance is determined at 600nm, survival rates (%) of the Lactobacillus plantarum YS3 in cholate=contain bile salt culture-medium is calculated by formula
OD600/ blank cultures OD600×100。
As a result as shown in table 2, survival rates of the Lactobacillus plantarum YS3 in the simulated gastric fluids of pH 3.0 and in various concentrations cholate
Lactobacillus bulgaricus is above, and survival rates of the Lactobacillus plantarum YS3 in the simulated gastric fluids of pH 3.0 is bulgarian milk bar
About 3 times of bacterium, and the survival rate in various concentrations cholate is about 8-11 times of lactobacillus bulgaricus, illustrates Lactobacillus plantarum
YS3 has the anti-hydrochloric acid in gastric juice ability and cholate tolerance more stronger than lactobacillus bulgaricus.
The anti-hydrochloric acid in gastric juice abilities of the Lactobacillus plantarum YS3 of table 2 and the detection of cholate tolerance
2nd, prevention effects of the Lactobacillus plantarum YS3 to activated carbon inducing mouse constipation
Choose body weight about 25g kunming mice 100, be equally divided into 5 groups, be normal group, constipation control group respectively, protect plus
Leah lactobacillus treatment group, Lactobacillus plantarum YS3 low concentrations treatment group and high concentration treatment group.Adapt to after raising 1 week, normal group
Diet is normally freely taken in constipation control group mice and is drunk water 2 weeks；Except normally freely taking in diet and drinking-water in this is 2 weeks
Outside, the 1.0 × 10 of the daily every gavage 2mL of lactobacillus bulgaricus treatment group mouse9CFU/mL lactobacillus bulgaricus, plants
The 1 × 10 of thing lactobacillus YS3 low concentrations treatment group and the daily every difference gavage 2mL of high concentration treatment group mouse8CFU/mL's
Lactobacillus plantarum YS3 and 1 × 109CFU/mL Lactobacillus plantarum YS3.After 2 weeks in addition to normal group mouse, other 4 groups of mouse are every
(temperature is 4 DEG C to the activated carbon water of day gavage 2mL, and 10% activated carbon is added into the water containing 10% gum arabic in mass ratio
Suspension is made in solution), while lactic acid bacteria processing each group continues gavage lactic acid bacteria, continue 3 days.
1st, influences of the Lactobacillus plantarum YS3 to mouse weight and excrement
In experimentation the timing of daily morning determine the body weight of all mouse, dietary intake, amount of drinking water, stool weight and
Excrement humidity.
Changes of weight is the important indicator that constipation occurs for mouse.As seen from Figure 3, in first 2 weeks each group mouse body weight
All showing between normal growth state, each group does not have notable difference；After activated carbon inducing constipation, not by activated carbon at
The normal group mouse weight of reason continues to increase, and remaining each group mouse weight declines, wherein the body of constipation control group mice
It is reduced by up to again, the body weight of Lactobacillus plantarum YS3 high concentration treatment group mouse is significantly higher than the guarantor of same concentration closest to normal group
Plus Leah lactobacillus treatment group, illustrate that Lactobacillus plantarum YS3 can suppress the mouse weight decline that constipation is caused, and effect is better than
Lactobacillus bulgaricus.
Defecation state most can significantly embody stool weight, granule number and water content in the degree of constipation, constipation state
It is important excrement state index, these index decreaseds show the exacerbation of constipation degree.As shown in table 3, the 1-14 days it is each
Stool weight, granule number and the water content of group mouse are not significantly different；After activated carbon inducing constipation, the 15-17 days normal groups
Stool weight, granule number and the water content highest of mouse, constipation control group are minimum, lactobacillus bulgaricus and Lactobacillus plantarum
YS3 can stool weight that significantly relief of constipation is caused, granule number and water content decline (P ＜ 0.05), but Lactobacillus plantarum
Stool weight, granule number and the water content of YS3 high concentration treatment group mouse are closest to normal group, and the guarantor for being significantly higher than same concentration adds
Leah lactobacillus treatment group, illustrates that Lactobacillus plantarum YS3 can suppress the stool in mice weight that constipation is caused, granule number and aqueous
Amount declines, and effect is better than lactobacillus bulgaricus.
Influences of the Lactobacillus plantarum YS3 of table 3 to stool in mice
Note：Alphabetical different expression group differences are significantly (P ＜ 0.05).
2nd, influences of the Lactobacillus plantarum YS3 to activated carbon propulsion rate and first grain melena efflux time
To the jejunitas 24h of all mouse implementations including normal group after 17th day gavage activated carbon water, but still give mouse
Freely take in the activated carbon water of all every gavage 0.2mL of mouse after drinking-water, 24h；Every group of half mouse (10) is real after 30min
Apply disconnected neck to put to death, take mice plasma standby, while taking small intestine to observe propulsion rate of the activated carbon in mouse small intestine, propulsion rate (%)
=activated carbon promotes length/total small intestinal length × 100；Every group of remaining 10 mouse continue to observe its discharge first grain melena when
Between.
Constipation causes the reduction of intestines peristalsis frequency, and excrement rests on the time increase of enteron aisle, causes harmful bacteria with excrement
Continuously bred for food, so as to threaten intestinal health, aggravate constipation.Activated carbon is promoted in small intestine after activated carbon inducing mouse constipation
Length and activated carbon propulsion rate can be used as the index for evaluating small intestine activity and constipation degree.As can be seen from Table 4, activated carbon is lured
Lead after constipation, lactobacillus bulgaricus and Lactobacillus plantarum YS3 can promote propulsion length of the activated carbon in mouse small intestine,
But the activated carbon propulsion rate highest of Lactobacillus plantarum YS3 high concentration treatment groups, is significantly higher than the processing of Lactobacillus plantarum YS3 low concentrations
Group and the lactobacillus bulgaricus treatment group (P ＜ 0.05) with concentration, illustrate that Lactobacillus plantarum YS3 can improve activated carbon small
Propulsion rate in mouse small intestine, and effect is better than lactobacillus bulgaricus.
The influence that the Lactobacillus plantarum YS3 of table 4 is promoted to mice with constipation intestines and stomach
Note：Alphabetical different expression group differences are significantly (P ＜ 0.05).
Constipation causes intestinal movement to slow down, and excrement holdup time in enteron aisle increases, and lengthens first grain melena efflux time,
Shorter first grain melena efflux time means that intestinal movement is more normal.As seen from Figure 4, the first grain melena discharge of normal group
Time is most short (83 ± 9min), and the first grain melena efflux time of constipation control group is most long (195 ± 28min), Lactobacillus plantarum YS3
The first grain melena efflux time (112 ± 19min) of high concentration treatment group is considerably shorter than Lactobacillus plantarum YS3 low concentration treatment groups
(147 ± 26min) and the lactobacillus bulgaricus treatment group (163 ± 22min) (P ＜ 0.05) with concentration, illustrates the newborn bar of plant
Bacterium YS3 can reduce the first grain melena efflux time of mice with constipation, with good constipation mitigation, and effect better than protecting plus
Leah lactobacillus.
3rd, influences of the Lactobacillus plantarum YS3 to mice serum MTL, Gas, ET, SS, AChE, SP and VIP level
The mice plasma of collection is taken, 4500rmp centrifugation 15min separate serum, mouse blood is determined by kit operating instruction
Clear MTL, Gas, ET, SS, AChE, SP and VIP level.MTL can stimulate the generation of pepsin and promote intestinal movement；
Gas can promote gastrointestinal secretion and gastrointestinal motility, promote pylorus relaxation, play a part of relief of constipation；ET is stable in antiotasis
Property and maintain to play an important role in basic cardiovascular system；SS can stimulate intestinal movement；AChE can adjust contraction of muscle and
Mucous secretion, can make loosening all muscles to promote excrement to discharge；SP is a kind of to contribute to the material of intestines peristalsis；Keep VIP
Normal contents in intestinal wall are also to stablize the important means of function of intestinal canal.
As can be seen from Table 5, the horizontal highest of MTL, Gas, ET, AChE, SP and VIP of normal group mice serum, SS levels
It is minimum；Constipation control group mice shows opposite trend；Lactobacillus bulgaricus and Lactobacillus plantarum YS3 can make above-mentioned
The serum levels of material are close to normal group level, but Lactobacillus plantarum YS3 effect is more notable, illustrate that Lactobacillus plantarum YS3 can
So that MT in serum L, Gas, ET, SS, AChE, SP and VIP level of mice with constipation is tried one's best, holding is normal, so that relief of constipation.
Influences of the Lactobacillus plantarum YS3 of table 5 to mice serum MTL, Gas, ET, SS, AChE, SP and VIP level
Note：Alphabetical different expression group differences are significantly (P ＜ 0.05).
4th, the influence that Lactobacillus plantarum YS3 is expressed mouse small intestine tissue mRNA
The small intestine of mouse is taken, colon's total serum IgE is extracted with RNAzol after crushing, is diluted to 1 μ g/ μ L；Take 2 μ L dilute
Total RNAs extraction liquid after releasing, sequentially adds 1 μ L oligodT18, RNase, dNTP, MLV enzyme and 10 μ L 5 × buffer, 37
DEG C 120min, 99 DEG C of 4min, 4 DEG C of 3min synthesis cDNA；Then use primer described in table 6, RT-PCR amplification c-Kit, SCF,
TRPV1, GDNF and NOS mRNA expression, internal reference is used as using housekeeping gene GAPDH；Finally with containing the bromination that mass ratio is 1%
The agar electrophoresis of second ingot checks pcr amplification product.
The RT-PCR primer sequence of table 6
ICC (Cajal interstitial cells) in constipation patient enteron aisle is less, and c-Kit is ICC Specific marker, is ICC
The key of propagation.SCF concentration is extremely important to ICC propagation, and ICC can not be grown in the environment of SCF is not present.Document report
ICC contents in road, mice with constipation colon are less, and the c-Kit expressions in colon also decline.Lactobacillus plantarum
YS3 mouse small intestine tissue c-Kit and SCF the mRNA influences expressed are shown in Fig. 5, constipation control group mice small intestine c-Kit and
SCF mRNA expression declines, and Lactobacillus plantarum YS3 can significantly raise c-Kit the and SCF mRNA expression in mouse small intestine, and
Acted on during high concentration more obvious.
TRPV1 with defecation it is verified that have substantial connection, and the release of neurotransmitter can be triggered by activating TRPV1, so that
Cause intestinal motility obstacle.TRPV1 expression increases are a notable phenomenons of damage of intestines, because gastrointestinal disorder causes enteron aisle to damage
Wound, makes constipation patient have higher TRPV1 expression.GDNF can adjust the function of gangliocyte, thus contribute to repair by
The enteron aisle of damage, can prevent constipation.NOS plays an important role to Gastrointestinal motility adjustment.NO increase can cause more serious colon to move
Power obstacle, control NOS can reduce NO content, be the feasible way for controlling constipation.Lactobacillus plantarum YS3 is to mouse small intestine group
Fig. 6 is shown in the influence for knitting middle TRPV1, GDNF and NOS mRNA expression, and normal group mouse has highest GDNF mRNA expression and most
Low TRPV1, NOS mRNA expression, and the GDNF mRNA of constipation control group mice express minimum, TRPV1 and NOS mRNA tables
Up to highest, relative to constipation control group, lactobacillus bulgaricus and Lactobacillus plantarum YS3 can raise GDNF mRNA expression
Expressed with TRPV1, NOS mRNA is lowered, but Lactobacillus plantarum YS3 effect is substantially better than lactobacillus bulgaricus.
Finally illustrate, the above embodiments are merely illustrative of the technical solutions of the present invention and it is unrestricted, although pass through ginseng
According to the preferred embodiments of the present invention, invention has been described, it should be appreciated by those of ordinary skill in the art that can
So that various changes are made to it in the form and details, the present invention limited without departing from appended claims
Spirit and scope.
<110>The college of education of Chongqing second
<120>Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared
<160>15
<210>1
<211>20
<212>DNA
<213>Artificial sequence
<220>
<223>Primer 2 7F
<400>1
agagtttgatcctggctcag 20
<210>2
<211>19
<212>DNA
<213>Artificial sequence
<220>
<223>Primer 1492R
<400>2
ggctaccttgttacgactt 19
<210>3
<211>1466
<212>DNA
<213>Lactobacillus plantarum YS3（Lactobacillus plantarum YS3）
<220>
<223>16S rDNA genetic fragments
<400>3
taatacatgc aagtcgaacg aactctggat tgattggtgc ttgcatcatg atttacattt 60
gagggagtgg cgaacgtgca atggcggctt tggtgagtaa cacgtgggaa acctgcccag 120
aagcggggaa taacacctgg aaacagatgc tataccgcat aacaacttgg accgcatggt 180
ccgagnttga aagatggctt cggctatcac ttttggatgg tcccgcggcg tattagctag 240
atggtggggt aacggctcac catggcaatg atacgtagcc gacctgagag ggtaatcggc 300
cacattggga ctgactcacg gccaaactcc tacgggaggc agcagtaggg aatcttccac 360
aatggacgaa gtctgatgga gcaacgccgc gtgagtgaaa agggtttcgg ctcgtaaact 420
ctgttgttaa agaagaacat atctgagagt aactgttcag gtattgacgg tatttaacag 480
aaagccacgg ctaactacgt gccagcagcc gcggtaatac gtaggtggca agcgttgtcc 540
ggatttattg ggcgtaaagc gagcgcaggc ggttttttaa gtctgatgtg aaagccttcg 600
gctcaaccga agaagtgcat cggaaatggg aaacttgagt gcagaagagg acagtggaac 660
tccattgtag cggtgaaatg cgtagatata tggaagaaca ccagtggcga aggcgctgtc 720
tggtctgtaa ctgacgctga ggctcgaaag tatggtagca aacaggatta gataccctgg 780
tatccatacc gtaaacgatg aatgctaagt gttggagggt ttccgccctt cagtgctgca 840
gctaacgcat taagcattcc gcctggggag tacggccgca aggctgaaac tcaaaggaat 900
tacgggggcc cgcacaagcg gtggagcatg tggttaaatt cgaagctacg cgaagaacct 960
taccaggtct tgacatacta tgcaaatcta agagattaga cgttcccttc ggggacatgg 1020
atacaggtgg tgcatggttg tcgtcagctc atgtcgtgag atgttgggtt agtcccgcac 1080
gagcgcaacc cttattatca gttgccagcg ttaagttggg cactctggtg agactgccgg 1140
tgacaaacgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg acctgggcta 1200
cacacgtgct acaatggatg gtacaacagt tgcgaactcg cgagagtaag ctaatctctt 1260
aaagccattc tcagttcgga ttgtaggctg caactcgcct acatgaagtc ggaatcgcta 1320
gtaatccgga tcagcatgcc gcggtgaata cgttcccggg ccttgacaca ccgcccgtca 1380
caccatgaga gtttgtaaca cccaaagtcg gtggggtaac cttttaggaa ccagccgcct 1440
aagggggaca gtagagtaag gtggat 1466
<210>4
<211>16
<212>DNA
<213>Artificial sequence
<220>
<223>The sense primer of RT-PCR amplification c-Kit mRNA expression
<400>4
agaccgaacg caactt 16
<210>5
<211>16
<212>DNA
<213>Artificial sequence
<220>
<223>The anti-sense primer of RT-PCR amplification c-Kit mRNA expression
<400>5
ggtgccatcc acttca 16
<210>6
<211>16
<212>DNA
<213>Artificial sequence
<220>
<223>The sense primer of RT-PCR amplification SCF mRNA expression
<400>6
aaactggtgg cgaatc 16
<210>7
<211>16
<212>DNA
<213>Artificial sequence
<220>
<223>The anti-sense primer of RT-PCR amplification SCF mRNA expression
<400>7
cacgggtagc aagaac 16
<210>8
<211>20
<212>DNA
<213>Artificial sequence
<220>
<223>The sense primer of RT-PCR amplification TRPV1 mRNA expression
<400>8
agcgagttca aagacccaga 20
<210>9
<211>20
<212>DNA
<213>Artificial sequence
<220>
<223>The anti-sense primer of RT-PCR amplification TRPV1 mRNA expression
<400>9
ttctccacca agagggtcac 20
<210>10
<211>19
<212>DNA
<213>Artificial sequence
<220>
<223>The sense primer of RT-PCR amplification GDNF mRNA expression
<400>10
ttttattcaa gccaccatc 19
<210>11
<211>17
<212>DNA
<213>Artificial sequence
<220>
<223>The anti-sense primer of RT-PCR amplification GDNF mRNA expression
<400>11
agcccaaacc caagtca 17
<210>12
<211>21
<212>DNA
<213>Artificial sequence
<220>
<223>The sense primer of RT-PCR amplification NOS mRNA expression
<400>12
ccacatctgg caggatgaga a 21
<210>13
<211>21
<212>DNA
<213>Artificial sequence
<220>
<223>The anti-sense primer of RT-PCR amplification NOS mRNA expression
<400>13
aggcacagaa ctgagggtac a 21
<210>14
<211>20
<212>DNA
<213>Artificial sequence
<220>
<223>The sense primer of RT-PCR amplification GAPDH mRNA expression
<400>14
cggagtcaac ggatttggtc 20
<210>15
<211>20
<212>DNA
<213>Artificial sequence
<220>
<223>The anti-sense primer of RT-PCR amplification GAPDH mRNA expression
<400>15
agccttctcc atggtcgtga 20
Claims (2)
1. Lactobacillus plantarum YS3 (Lactobacillus plantarum YS3), deposit number is CCTCC NO：M2016749.
2. applications of the Lactobacillus plantarum YS3 in the food of Constipation is prepared described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710542452.6A CN107099491A (en) | 2017-07-05 | 2017-07-05 | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710542452.6A CN107099491A (en) | 2017-07-05 | 2017-07-05 | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107099491A true CN107099491A (en) | 2017-08-29 |
Family
ID=59663413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710542452.6A Pending CN107099491A (en) | 2017-07-05 | 2017-07-05 | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107099491A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109700033A (en) * | 2019-03-04 | 2019-05-03 | 山东环亿生物科技有限公司 | A kind of adjusting enteron aisle, probiotic composition of prevent constipation and preparation method thereof |
| CN110692726A (en) * | 2018-07-10 | 2020-01-17 | 重庆第二师范学院 | Lactobacillus plantarum CQPC01 and application thereof in preparation of food for improving constipation |
| CN110699271A (en) * | 2018-07-10 | 2020-01-17 | 重庆第二师范学院 | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106906165A (en) * | 2017-04-25 | 2017-06-30 | 重庆第二师范学院 | A kind of Lactobacillus plantarum and its application in the food for preparing Constipation |
-
2017
- 2017-07-05 CN CN201710542452.6A patent/CN107099491A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106906165A (en) * | 2017-04-25 | 2017-06-30 | 重庆第二师范学院 | A kind of Lactobacillus plantarum and its application in the food for preparing Constipation |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110692726A (en) * | 2018-07-10 | 2020-01-17 | 重庆第二师范学院 | Lactobacillus plantarum CQPC01 and application thereof in preparation of food for improving constipation |
| CN110699271A (en) * | 2018-07-10 | 2020-01-17 | 重庆第二师范学院 | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation |
| CN110699271B (en) * | 2018-07-10 | 2022-11-01 | 善恩康生物科技（苏州）有限公司 | Lactobacillus plantarum CQPC02 and application thereof in preparation of food for improving constipation |
| CN109700033A (en) * | 2019-03-04 | 2019-05-03 | 山东环亿生物科技有限公司 | A kind of adjusting enteron aisle, probiotic composition of prevent constipation and preparation method thereof |
| CN109700033B (en) * | 2019-03-04 | 2021-06-04 | 山东环亿生物科技有限公司 | Probiotic composition for regulating intestinal tract and preventing constipation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104232544B (en) | Solation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk | |
| CN107099492A (en) | Lactobacillus plantarum YS4 and its application in the food of Constipation is prepared | |
| CN105420152B (en) | Lactobacillus plantarum N3117, its screening technique and application | |
| CN109182207B (en) | Lactobacillus acidophilus La-SJLH001 with probiotic functions of regulating blood sugar level, cholesterol level and the like and application thereof | |
| CN107893044A (en) | One plant of bifidobacterium longum and its application | |
| US9540609B2 (en) | Lactobacillus rhamnosus food grade bacteria | |
| CN107619811A (en) | Lactobacillus plantarum CCFM200 bacterial strains and application | |
| CN1568365A (en) | Composition comprising a lactobacillus pentosus strain and uses thereof | |
| CN114480229B (en) | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof | |
| CN106906165A (en) | A kind of Lactobacillus plantarum and its application in the food for preparing Constipation | |
| CN104805040B (en) | A kind of bacillus subtilis formulation and preparation method and application | |
| CN107475162A (en) | Lactobacillus rhamnosus and its application with the high inhibitory activity of DPP IV | |
| CN109749957A (en) | A kind of preparation and application of the lactobacillus gasseri preparation with aquatic pathogenic bacterium antagonistic properties | |
| CN112029674A (en) | Bacillus coagulans BC01 for improving intestinal microecology and relieving constipation and application thereof | |
| CN109628346A (en) | Lactobacillus fermenti CQPC04 and its application in the food that preparation improves constipation | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| AU2014254813A1 (en) | Composition containing bacterium belonging to genus Lactobacillus | |
| CN107099491A (en) | Lactobacillus plantarum YS3 and its application in the food of Constipation is prepared | |
| CN107227275A (en) | A kind of lactobacillus fermenti HY01 and application thereof | |
| CN113755409A (en) | Bifidobacterium longum for relieving insulin resistance and application thereof | |
| CN101851593B (en) | Lactobacillus planetarium strain LP28 and application thereof in mitigation of anaphylactic reaction | |
| CN100558883C (en) | New bacterial strain with genus bifidobacterium of the ability that produces glutamine | |
| CN107028988A (en) | Applications of the Lactobacillus plantarum YS1 in the food or medicine of prevention ulcerative colitis is prepared | |
| CN107267416A (en) | Lactobacillus plantarum YS2 and its application in the food of Constipation is prepared | |
| CN109362882B (en) | Lactobacillus fermentum CQPC07 and application thereof in preparing food or medicine for improving ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170829 |